Pfizer

News

ICER identifies new crop of 'unsupported' drug price rises

Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.

News

BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer

News

Pfizer elevates Chris Boshoff to top R&D role

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

News

Incyte blocks US launch of Sun Pharma's alopecia drug

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.

News

Alarm bell rings for GSK as US policy dents RSV jab sales

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

ICER identifies new crop of 'unsupported' drug price rises

BridgeBio poised to challenge Pfizer after Attruby approval

Pfizer elevates Chris Boshoff to top R&D role

Pfizer bags EU okay for haemophilia drug Hympavzi

Incyte blocks US launch of Sun Pharma's alopecia drug

Alarm bell rings for GSK as US policy dents RSV jab sales

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks